Neurological disorder

Qbtech: Telehealth is Not Jeopardizing ADHD Care - It’s Expanding It

Retrieved on: 
Monday, June 12, 2023
Public Policy, Government, Mental Health, Health, Healthcare Reform, FDA, Telemedicine, Virtual Medicine, Pharmaceutical, Consensus, Interview, WebMD, Perception, Policy, Prescription, COVID, MPAS, Patient, Head, Diagnosis, Neurological disorder, Commercial Operating System, Dietary supplement, ADHD

Despite the common perception that ADHD is overdiagnosed, the opposite is, in fact, true.

Key Points: 
  • Despite the common perception that ADHD is overdiagnosed, the opposite is, in fact, true.
  • Increasing rates of ADHD are not due to over-care but rather increased awareness of the condition.
  • In response to the comments from Dr. Califf and the continued dialogue faulting telehealth for the issues in ADHD, executives from Qbtech , the global leader in objective ADHD testing, shared their perspectives on improving the quality of care for ADHD.
  • Offering telehealth for ADHD treatment removes the many barriers to care that patients face,” shared Dr. Griffith Jones DMSc, MPAS, PA-C, Fox Fern ADHD Clinic .

Global Medical Display Market to 2028 - Growing Demand for Digital Healthcare Fuels the Sector

Retrieved on: 
Friday, June 9, 2023
ASP, Cancer, LCD, Radiology, USD, Hospital, OLED, Conditional sentence, Neurological disorder, Digital, Television, Medical imaging

The global market for Medical Display Market is estimated to grow significantly.

Key Points: 
  • The global market for Medical Display Market is estimated to grow significantly.
  • The expansion of the medical display market is driven by various factors, including increasing technological advancements, growing demand for digital healthcare, increasing chronic diseases, increasing diagnostic imaging imaging procedures, and a rising demand for increased diagnostic accuracy.
  • The market for Medical Display Market is characterized into five segments such as technology, panel size, resolution, color and application.
  • In response to growing healthcare needs, advancements in medical treatments, and a growing understanding of the advantages of medical displays, the medical display technology is expanding in Asia Pacific.

Retinalgenix Technologies, Inc. Expands Team to Hasten the Launch of DNA/GPS

Retrieved on: 
Wednesday, June 7, 2023
Retina, DNA, CT, Diabetes, HIPPA, Pharmacogenomics, Stroke, OTCQB, PET, Intelligence, Paratriathlon, Risk, Science, MRI, Alzheimer's disease, Dementia, Parkinson's disease, Data analysis, Hospital, Systemic disease, MD, Patient, Laboratory, Deep learning, Genetic testing, Neurological disorder, Diagnosis, HIPAA, Kidney disease, Pharmaceutical industry, Television, Medical imaging

The application is expected to allow patients to obtain their genetic systemic bio-markers privately, discreetly, and confidentially.

Key Points: 
  • The application is expected to allow patients to obtain their genetic systemic bio-markers privately, discreetly, and confidentially.
  • His experience in the management of pharmacogenetics and imaging in a HIPPA-compliant database will be a great asset to RetinalGeniX,” said Dr. Larry Perich, Lead Investigator and Co-developer of DNA/GPS.
  • Owen has integrated his skill set by optimizing cloud-based offerings and designing top-notch security solutions.
  • “We are thrilled to announce the addition of Owen Watson to our team.

FUJIFILM Cellular Dynamics Introduces First-of-its-Kind Human iPSC-derived Blood-Brain Barrier Isogenic Kit

Retrieved on: 
Thursday, June 1, 2023
Astrocyte, Drug development, Central nervous system, Medium (website), IPSC, Pericyte, Stroke, 3D, Blood–brain barrier, DSM-IV codes, Pharmacokinetics, Hope, Physiology, Traffic barrier, Brain, Research, Cell, CNS, Neuroscience, Dementia, Animal, ICEL Psalter, Permeability, Patient, Drug discovery, Microglia, Neurological disorder, Migraine, WHO, IPS, Meningitis, World Health Organization, Medical imaging

The first-of-its-kind kit models the human blood-brain barrier and can advance drug discovery, drug development and medical research for central nervous system (CNS) disorders.

Key Points: 
  • The first-of-its-kind kit models the human blood-brain barrier and can advance drug discovery, drug development and medical research for central nervous system (CNS) disorders.
  • The iCell Blood-Brain Barrier Isogenic Kit is an off-the-shelf, ready to use, human iPSC-derived cell model that has barrier integrity and functionality consistent with in vivo physiological properties.
  • The iCell Blood-Brain Barrier Isogenic Kit is commercially available and will begin shipping by the end of June 2023.
  • To learn more about FUJIFILM Cellular Dynamics’ blood-brain barrier cellular model, you can visit https://www.fujifilmcdi.com/icell-blood-brain-barrier-kit-coming-soon/ .

Using Nerivio® for Migraine Prevention Results in Significant Clinical and Cost-Saving Benefits for Patients, Insurers, and Employers, According to a New Health Economics Study

Retrieved on: 
Tuesday, May 16, 2023
Presenteeism, Migraine, Insurance, REN, Therapy, Life, International Classification of Functioning, Disability and Health, Stanford University, Patient satisfaction, Headache (journal), Absenteeism, AHS, Quality of life, Research, Brain, Headache, Journal of Medical Economics, Health, Journal, Stanford University Medical Center, Work, MD, Patient, Pain management, CPM, Neurological disorder, FDA, Health insurance, Pharmaceutical industry, Medical imaging

NETANYA, Israel and BRIDGEWATER, N.J., May 16, 2023 /PRNewswire/ -- Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other pain conditions, announced the results of a recent study published in the Journal of Medical Economics, showing that Nerivio®, a novel Remote Electrical Neuromodulation (REN) wearable, provides significant cost savings in addition to clinical benefits when used as a preventive migraine treatment.

Key Points: 
  • The randomized, double-blind, placebo-controlled trial aimed to assess the clinical benefits and associated cost savings from use of REN with Nerivio for migraine prevention.
  • Participants treated with either Nerivio or a placebo device every other day for prevention of migraine.
  • Health insurance systems and employers should consider the powerful financial incentives that come with this drug-free migraine treatment."
  • Each treatment lasts 45 minutes and is applied every other day for prevention or at the start of a migraine attack for acute treatment.

MeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting

Retrieved on: 
Tuesday, May 16, 2023
Inflammation, Temperature, GH, Cryogenic electron microscopy, Endocrine gland, Risk, Cell, ALS, Virus, Gene, DSM-IV codes, Research, Gene expression, Ion, AUC, American Society of Gene and Cell Therapy, Liver, Neoplasm, AAV2, Kinetics, Death, Poster, HPLC, Genome, Safety, Neuron, Growth hormone, Muscular dystrophy, STR, Transfection, AAV, Hepatocyte, CAR, Sequence, Animal, CMV, Immune system, Cancer, AEX, Plasmid, PH, Neurological disorder, Human, NF-κB, Riboswitch, LDH, DSW, RNA, Skeletal muscle, CAG, Sure, Annual general meeting, Mouse, Society, FTD, Vaccine, Publication

RiboCAR is a synthetic riboswitch-based gene regulation system for precise regulation of CAR expression levels in CAR-T cell therapy via orally available small molecule.

Key Points: 
  • RiboCAR is a synthetic riboswitch-based gene regulation system for precise regulation of CAR expression levels in CAR-T cell therapy via orally available small molecule.
  • We demonstrate that with a bioavailable small molecule inducer, CAR-T activity can be precisely tuned and “remotely” controlled in vivo.
  • However, excessive amounts of transgene from unregulated vectors may limit the breadth of applicability of gene therapy.
  • Collectively, these results show we have established a robust platform to screen engineered promoters for applications to skeletal muscle gene therapies.

Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 11, 2023
Biotechnology, General Health, Neurology, Health, Pharmaceutical, Disease, National Defense Authorization Act, Regulation Fair Disclosure, European Medicines Agency, Policy, Disclosure, European Directive on Traditional Herbal Medicinal Products, Brain, Research, Marketing, Wolfram syndrome, Medication, Committee, EMA, Globalization, Walking, Investment, Physician, PEGASUS, Committee for Medicinal Products for Human Use, Webcast, AMX0035, Growth, Neurological disorder, MAA, Palsy, ALS, Regulation, PSP, Safety, CHMP, Pharmaceutical industry, Cryptocurrency, PHOENIX, Amylyx Pharmaceuticals, Wolfram

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the first quarter ended March 31, 2023.
  • The Company continues to expect an opinion from the CHMP mid-year and a decision in the third quarter of 2023 at the earliest.
  • Financial Results for the First Quarter Ended March 31, 2023
    For the three months ended March 31, 2023, net product revenue was $71.4 million and cost of sales were $5.3 million.
  • Amylyx’ management team will host a conference call and webcast today, May 11, 2023, at 4:30 p.m.

Sunrise House Treatment Center Welcomes Anna-Liisa Bramwell to Amplify Role of Nutrition in Addiction Treatment

Retrieved on: 
Wednesday, May 10, 2023
Bramwell, Wernicke–Korsakoff syndrome, Mineral, Malnutrition, Nutrient, Grain boundary strengthening, Brain, Dopamine, Absorption, Thiamine, Cocaine, Metabolism, Patient, Liver disease, Micronutrient, Neurological disorder, Serotonin, Health, Mental health, Dietary supplement

LAFAYETTE, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Sunrise House Treatment Center, a leading provider of co-occurring mental health and addiction treatment services in New Jersey, has recently announced the addition of Anna-Liisa Bramwell to the facility staff.

Key Points: 
  • LAFAYETTE, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Sunrise House Treatment Center, a leading provider of co-occurring mental health and addiction treatment services in New Jersey, has recently announced the addition of Anna-Liisa Bramwell to the facility staff.
  • Bramwell, a registered dietician, will act as an integral part of the clinical team to address patients’ nutritional health during their course of treatment.
  • The utilization of registered dieticians is a growing trend in addiction treatment due to the nutritional deficiencies that often accompany or are caused by an alcohol or substance use disorder.
  • “As we continue to enhance our clinical care and expand our treatment offerings at Sunrise House, it made perfect sense to incorporate nutritional wellness into our patients’ care,” said Marcey Davis, interim CEO of Sunrise House Treatment Center.

Baszucki Group Partners with Stony Brook University on Neuroblox Platform to Revolutionize Treatments for Brain Disorders

Retrieved on: 
Monday, May 8, 2023
David Baszucki, Learning, Life, Schizophrenia, Neurological disorder, DSM-IV codes, Stony Brook University, Research, Brain, Biomedical engineering, Ketosis, Tablet, Neuroscience, Dementia, Health, Mental health, Bipolar disorder, Ketone, Medical imaging, Roblox, Lilium

STONY BROOK, N.Y., May 8, 2023 /PRNewswire/ -- Today, Stony Brook University announced a philanthropic gift to develop Neuroblox, a software platform developed by biomedical engineer and neuroscientist Lilianne "Lily" Mujica-Parodi that will model brain circuits to treat brain disorders. The gift was made possible by David Baszucki, founder and chief executive officer of Roblox, and his wife, bestselling author Jan Ellison Baszucki.

Key Points: 
  • STONY BROOK, N.Y., May 8, 2023 /PRNewswire/ -- Today, Stony Brook University announced a philanthropic gift to develop Neuroblox , a software platform developed by biomedical engineer and neuroscientist Lilianne "Lily" Mujica-Parodi that will model brain circuits to treat brain disorders.
  • The gift was made possible by David Baszucki, founder and chief executive officer of Roblox, and his wife, bestselling author Jan Ellison Baszucki.
  • The platform will allow researchers to explore the complexities of brain-based disorders by providing a blueprint for individualized care.
  • The $6.2 million investment from the Baszucki family includes $3.2 million to help build and launch Neuroblox and $3 million to create the Baszucki Endowed Chair for Metabolic Neuroscience at Stony Brook University.

Fur seals on a remote island chain are exposed to huge amounts of toxic heavy metals – yet somehow, they're healthy

Retrieved on: 
Monday, May 1, 2023
Phytoplankton, Human, Travel, Diet, Zinc, Metal, Zooplankton, Mammal, Eating, Chlorophyll, Mercury, Bone pain, Hepatopancreas, Plant, Sunlight, Climate change, Animal, Hunting, Population, Iron, Volcanic explosivity index, Metabolism, Risk, Mining, Food chain, Cadmium poisoning, Micronutrient, Neurological disorder, Weather, Juan, Cadmium, Dietary supplement, Rare-earth element, Fertilizer

Their mysterious nature owes a lot to their seclusion on an archipelago of the same name 600km off the Chilean coast.

Key Points: 
  • Their mysterious nature owes a lot to their seclusion on an archipelago of the same name 600km off the Chilean coast.
  • These remote islands are situated in a protected national park – the last place you might expect to find animals exposed to high levels of pollution.
  • This species is ingesting exceptionally high concentrations of these toxic heavy metals through its diet, but how they enter the food chain proved to be more complicated than we anticipated.

Where are the heavy metals coming from?

    • These heavy metals are highly toxic even in small amounts, and they have few known biological uses.
    • Heavy metals occur naturally in the Earth’s crust and are emitted by volcanic eruptions or as a result of rocks being worn down by the weather.
    • These molluscs can accumulate large quantities of heavy metals in their kidneys and, especially, in an organ known as the hepatopancreas.
    • Unlike humans, who largely only eat the tentacles, fur seals consume the whole prey, including the heavy metal-rich organs.

A new mystery

    • As expected, Juan Fernández fur seal skeletons were loaded with cadmium.
    • But, to our surprise, we could not find any other mineral changes which would be expected in an animal suffering from cadmium poisoning.
    • Every Wednesday, The Conversation’s environment editor writes Imagine, a short email that goes a little deeper into just one climate issue.